Stock of the Day: Could Conatus Pharmaceuticals Inc Change Direction After Today’s Significant Increase?

Stock of the Day: Could Conatus Pharmaceuticals Inc Change Direction After Today's Significant Increase?

The stock of Conatus Pharmaceuticals Inc (NASDAQ:CNAT) is a huge mover today! About 703,766 shares traded hands. Conatus Pharmaceuticals Inc (NASDAQ:CNAT) has risen 10.11% since March 1, 2016 and is uptrending. It has outperformed by 0.87% the S&P500.
The move comes after 6 months positive chart setup for the $46.53 million company. It was reported on Oct, 4 by We have $4.21 PT which if reached, will make NASDAQ:CNAT worth $44.67M more.

Analysts await Conatus Pharmaceuticals Inc (NASDAQ:CNAT) to report earnings on November, 2. They expect $-0.32 earnings per share, down 3.23% or $0.01 from last year’s $-0.31 per share. After $-0.30 actual earnings per share reported by Conatus Pharmaceuticals Inc for the previous quarter, Wall Street now forecasts 6.67% negative EPS growth.

Conatus Pharmaceuticals Inc (NASDAQ:CNAT) Ratings Coverage

Out of 4 analysts covering Conatus Pharma (NASDAQ:CNAT), 4 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. $15.0 is the highest target while $6 is the lowest. The $10 average target is 365.12% above today’s ($2.15) stock price. Conatus Pharma has been the topic of 4 analyst reports since September 22, 2015 according to StockzIntelligence Inc. The stock has “Buy” rating given by Roth Capital on Friday, July 1. The rating was initiated by H.C. Wainwright on Tuesday, September 22 with “Buy”. As per Thursday, November 5, the company rating was maintained by Stifel Nicolaus.

According to Zacks Investment Research, “Conatus Pharmaceuticals, Inc. is a biotechnology company. It is focused on developing and commercializing medicines to treat liver disease. The Company is developing its lead compound, emricasan, for the treatment of patients in orphan populations with chronic liver disease and acute exacerbations of chronic liver disease. Conatus Pharmaceuticals, Inc. is headquartered in San Diego, California.”

Insitutional Activity: The institutional sentiment increased to 2.29 in Q2 2016. Its up 1.68, from 0.61 in 2016Q1. The ratio is positive, as 4 funds sold all Conatus Pharmaceuticals Inc shares owned while 3 reduced positions. 5 funds bought stakes while 11 increased positions. They now own 5.01 million shares or 0.94% more from 4.96 million shares in 2016Q1.
Ladenburg Thalmann Svcs Inc accumulated 0% or 500 shares. Goldman Sachs Grp Inc Inc accumulated 14,047 shares or 0% of the stock. Blackrock Institutional Trust Na holds 0% of its portfolio in Conatus Pharmaceuticals Inc (NASDAQ:CNAT) for 63,163 shares. Northern Tru, a Illinois-based fund reported 21,968 shares. Bridgeway Capital last reported 0% of its portfolio in the stock. Vanguard Gp Inc Inc last reported 0% of its portfolio in the stock. Axa, a France-based fund reported 1.09 million shares. Jacobs Levy Equity Inc holds 78,151 shares or 0% of its portfolio. Gru One Trading L P holds 0% of its portfolio in Conatus Pharmaceuticals Inc (NASDAQ:CNAT) for 28,134 shares. Moreover, Deutsche Comml Bank Ag has 0% invested in Conatus Pharmaceuticals Inc (NASDAQ:CNAT) for 14,939 shares. D E Shaw accumulated 0% or 45,139 shares. Mpm Asset Mngmt Limited Liability Corporation has 1.19M shares for 0.8% of their US portfolio. The New Jersey-based Financial Architects has invested 0% in Conatus Pharmaceuticals Inc (NASDAQ:CNAT). Polar Capital Limited Liability Partnership has 156,531 shares for 0.01% of their US portfolio. Commercial Bank Of New York Mellon Corp holds 0% or 86,296 shares in its portfolio.

More news for Conatus Pharmaceuticals Inc (NASDAQ:CNAT) were recently published by:, which released: “3 Stocks to Watch on Tuesday:, Inc. (CRM), TerraForm Power, Inc …” on October 04, 2016.‘s article titled: “15 Stocks Moving In Tuesday’s Pre-Market Session” and published on October 04, 2016 is yet another important article.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Leave a Comment